European Journal of Cancer
Volume 43, Issue 14 , Pages 2074-2081 , September 2007

Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours

  • F. Pein

      Affiliations

    • Institut Regional du Cancer Nantes Atlantique, Dept de Recherche Therapeutique, CLCC Rene Gauducheau, Nantes, France
    • ,
  • R. Pinkerton

      Affiliations

    • Queensland Childrens Cancer Centre, Royal Childrens and Mater Childrens Hospitals, Brisbane, Queensland 4101, Australia
    • Corresponding Author InformationCorresponding author: Tel.: +617 3840 3424; fax: +617 3840 8012.
    • ,
  • P. Berthaud

      Affiliations

    • Novartis Pharma, Basel, Switzerland
    • ,
  • K. Pritchard-Jones

      Affiliations

    • Department of Paediatrics, Royal Marsden NHS Trust and Institute of Cancer Research, Downs Road, Sutton, United Kingdom
    • ,
  • G. Dick

      Affiliations

    • Department of Paediatrics, Royal Marsden NHS Trust and Institute of Cancer Research, Downs Road, Sutton, United Kingdom
    • ,
  • G. Vassal

      Affiliations

    • Institut Gustave Roussy, Department of Paediatric and Adolescent Oncology and UPRES-EA-2710, Parmacology and New Cancer Therapies, Villejuif, France

Received 3 October 2006 ,Revised 25 June 2007 ,Accepted 4 July 2007.

References 

  1. Pinkerton CR. Multidrug resistance reversal in childhood malignancies – potential for a real step forward?. Eur J Cancer. 1996;32:161–167
  2. Cowie FJ, Pritchard-Jones K, Renshaw J, Pinkerton CR. Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines. Int J Oncol. 1998;12:1143–1149
  3. Cocker HA, Pinkerton CR, Kelland LR. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. Br J Cancer. 2000;83:338–345
  4. Cagliero E, Ferracini R, Morello E, et al. Reversal of multi-drug resistance using Valspodar (PSC-833) and doxorubicin in osteosarcoma. Oncol Rep. 2004;12:1023–1031
  5. Cairo MS, Siegel S, Anas N, Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine and continuous infusion VP-16 in drug-resistant pediatric tumours. Cancer Res. 1989;49:1063–1066
  6. Theis JG, Liau Chu M, Chan HS, Doyle J, Greenberg ML, Koren G. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumour resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol. 1995;13:2508–2516
  7. Bisogno G, Cowie F, Boddy A, Thomas HD, Dick G, Pinkerton CR. High-dose cyclosporin with etoposide – toxicity and pharmacokinetic interaction in children with solid tumours. Br J Cancer. 1998;77:2304–2309
  8. Boot DJ, Dennis IF, Twentyman PR, et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol. 1996;14:610–618
  9. Kornblau SM, Estey E, Madden T, et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC 833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol. 1997;15:1796–1802
  10. Lee EJ, George SL, Caliguiri M, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC 833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. J Clin Oncol. 1999;17:2831–2839
  11. Chauncey TR, Rankin C, Anderson JE, et al. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide and the MDR modulator PSC 833: a southwest oncology group study 9617. Leuk Res. 2000;24:567–574
  12. Fracasso PM, Westerveldt P, Fears CA, et al. Phase I study of paclitaxel in combination with a multidrug resistance modulator PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol. 2000;18:1124–1134
  13. Del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gill A, et al. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2002;41:115–135
  14. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC. Pharmacologic interactions between the resistance-modifying cyclosporine SCZ PSC 833 and etoposide (VP 16-213) and enhance in vivo cytostatic activity and toxicity. Int J Cancer. 1992;51:433–438
  15. Kornblau SM, Estey E, Madden T, et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC 833 in relapsed or refractory acute myelogenous leukaemia. J Clin Oncol. 1997;15:1796–1802
  16. Phillips M, Flamant F, Sommelet-Olive D, Pinkerton CR. Phase II study of rapid scheduled etoposide in paediatric soft tissue sarcomas. Eur J Cancer. 1995;31(5):782–784
  17. Phillips MB, Pinkerton CR. Pilot study of a rapid etoposide-cisplatin regimen in paediatric soft tissue sarcomas. Eur J Cancer. 1992;28:399–403
  18. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987;84:7735–7738
  19. Le Bot MA, Kernaleguen D, Robert J, Berlion M, Riche C. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance. Cancer Chemother Pharmacol. 1994;35:53–58
  20. Gioccone G, Linn SC, Welink J, et al. A dose finding and pharmacokinetic study of reversal of multidrugf resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumours. Clin Cancer Res. 1997;3:2005–2015
  21. Cowie F, Pinkerton CR. Enhanced toxicity of dactinomycin and vincristine by cylosporin given to reverse multidrug resistance. J Clin Oncol. 1994;12:1988–1999
  22. Hu XF, Slater A, Wall DM, et al. Rapid up-regulation of MDR1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer. 1995;71:931–936
  23. Hu XF, Slater A, Rischin D, Kantharidis P, Parkin JD, Zalcberg J. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br J Cancer. 1999;79:831–837
  24. Van der Holt B, Lowenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukaemia (AML), in relation to MDR1 status at diagnosis. Blood. 2005;106:2646–2654
  25. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukaemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004;22:1078–1086
  26. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukaemia younger then 60 years: final induction results of Cancer and Leukaemia Group B Study 9621. J Clin Oncol. 2004;22:4290–4301
  27. Advani R, Lum BL, Fisher GA, et al. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multi-drug resistance. Ann Oncol. 2005;16:1968–1973
  28. Fracasso PM, Blum KA, Ma MK, et al. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br J Cancer. 2005;93:46–53

PII: S0959-8049(07)00526-6

doi: 10.1016/j.ejca.2007.07.003

European Journal of Cancer
Volume 43, Issue 14 , Pages 2074-2081 , September 2007

Article Tools

* Image Usage & Resolution